March 31, 2025 – The FDA has approved a new drug as a preventive treatment to reduce bleeding episodes in people with certain types of hemophilia. This first-of-its-kind injectable drug offers ...

The drug fitusiran, which will go by the brand name Qfitlia, is the first new treatment for both types of hemophilia — A and B. It can also be given to both patients who have antibodies that ...

Efanesoctocog alfa, prescribed weekly and exorbitantly priced, is found not cost-effective in treating severe hemophilia A.

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

As a small interfering RNA (siRNA) drug, Qfitlia mimics a natural ... 30,000 people in the U.S. with hemophilia, including approximately a quarter with type B. As an X chromosome-linked condition ...

On the occasion of World Hemophilia Day, let us reflect on this disorder and examine the current state of treatment for ...

The U.S. Food and Drug Administration on Friday approved ... episodes in adult and pediatric patients (aged 12 or older) with hemophilia A or B with or without factor VIII or IX inhibitors.